Sacituzumab govitecan plus cisplatin for recurrent ovarian/endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian or endometrial cancer that came back after at least 6 months from your last platinum chemotherapy.
- You are a woman 18 years or older.
- You are healthy enough for daily activities (able to care for yourself) and expected to live at least 12 more weeks.
- Your cancer can be seen on a CT scan (measurable or evaluable disease).
- Your blood counts and kidney/liver function are within a certain range (doctors will check).
- You have not had prior treatment with the study drug (sacituzumab govitecan) or similar drugs.
- You must not be pregnant or breastfeeding, and you must use effective birth control during and 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
This study tests a drug called sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) for people with mesothelioma that has already been treated with other therapies. The goal is to see if the drug can shrink tumors and help control the disease.
This trial tests a combination of two drugs—sacituzumab govitecan (targeted therapy) and capecitabine (chemotherapy)—for people with advanced stomach, colon, or pancreatic cancer that has stopped responding to standard treatments.
This trial tests a drug called IMMU-132, which targets a protein (TROP-2) found on some ovarian cancer cells. It may help people whose cancer has returned or spread and who have not responded well to standard treatments.
This trial tests whether a new drug combination (sacituzumab govitecan plus bevacizumab) works better than the usual chemotherapy for ovarian cancer that has come back after platinum treatment and PARP inhibitor maintenance. It may offer a new option for people with certain genetic markers (BRCA mutations or HRD).
This trial tests two targeted drugs — sacituzumab tirumotecan (which attacks cancer cells) and bevacizumab (which cuts off blood supply to tumors) — for ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination helps shrink or slow the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.